FOLH1 and metastatic prostate carcinoma: PERTINENT FINDINGS: We describe the case of a patient with metastatic prostate cancer with many sites of disease who declined ADT, chemotherapy, and primary local treatment to the prostate gland and instead received two cycles of up-front [177Lu]Lu-PSMA-617.